Physician profile
Mark Kelly
NPI 1093889263
$4,608.21
in general payments reported to CMS, 2019-2025
14 companies · $3,388 in 2025
The $3,388 reported for 2025 was more than what 88% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $12.15 · 2021: $21.38 · 2022: $265 · 2023: $305 · 2024: $482 · 2025: $3,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Food and Beverage: $1,291 · Travel and Lodging: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Food and Beverage | $1,290.74 |
| Travel and Lodging | $884.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $3,240.78 | 2025 | |
| Procept Biorobotics Corporation | $288.99 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Angiodynamics, INC. | $266.41 | 2024 | Nanoknife |
| Janssen Biotech, INC. | $247.04 | 2022-2025 | Carvykti, Rybrevant |
| Boston Scientific Corporation | $147.48 | 2019-2023 | Rezum Generator |
| Progenics Pharmaceuticals, INC. | $118.23 | 2022 | |
| Astellas Pharma US INC | $93.12 | 2023 | Xtandi |
| Sumitomo Pharma America, INC. | $70.39 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $45.02 | 2019-2021 | |
| Dentsply Ih Ab | $22.57 | 2025 | Lofric |
| Biocompatibles, INC. | $21.40 | 2019 | |
| Pfizer INC. | $17.13 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.50 | 2024 | |
| Urogen Pharma, INC. | $14.15 | 2023 | Jelmyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.